Share

Precision Medicine: Time for a European Transformation

An article to be published in the Journal of Biomedicine explains the imbalance between the latest scientific evolutions and real life patient issues. Even now, regulatory agencies, governments and funding agencies underestimate the integration of scientific research into health care and vice versa.

Clinical research has seen a remarkable evolution in the last few years. The increasing knowledge with the emergence of new technologies has enabled a greater focus on the identification of mechanism-based therapies. However, the issues of drug development are too complex to be tackled in isolation.

Large amounts of data and optimized information technology solutions stored into centralized platforms would help managing the specific patient needs. Decisions taken exclusively from real-life data carry uncertainty. Health care systems cannot afford such uncertainty and therefore are prone to support the solutions coming from research and integrate them into care, in order to improve efficiency.

The article will explain the elements need for optimal access to clinical trials and enable benchmarking clinical research as well as real life. Ensuring a healthy alignment of competences will help identifying research findings leading to better and affordable health. Solutions that bring the latest scientific results to patient care will require new partnership models where stakeholders work on a more open agenda even in the early stage process of development. It is urgent that European bodies who have the capacity to stimulate such integrations get their acts together if we want to make precision medicine an assigned rather than a fortuitous happening, generating false hope for the patients and the scientific community. A re-discussion of the architecture of the process from “omics” to health technology and economics based on outcome-focused systems is really needed. A wise use of anti-cancer treatment will inevitably impact the value of cancer care as well as health care systems.

Come at 1st EAPM Congress (27 – 30 November 2017, Belfast North Ireland) and visit our stand 12 in the exhibition hall.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023